Literature DB >> 30315124

Temporal autoregulation during human PU.1 locus SubTAD formation.

Daniel Schuetzmann1, Carolin Walter2, Boet van Riel1, Sabrina Kruse3, Thorsten König1, Tabea Erdmann4, Alexander Tönges1, Eric Bindels5, Andre Weilemann4, Claudia Gebhard6, Klaus Wethmar4, Chiara Perrod7, Julia Minderjahn6, Michael Rehli6, Ruud Delwel5, Georg Lenz4, Stefan Gröschel3,8,9, Martin Dugas2, Frank Rosenbauer1.   

Abstract

Epigenetic control of gene expression occurs within discrete spatial chromosomal units called topologically associating domains (TADs), but the exact spatial requirements of most genes are unknown; this is of particular interest for genes involved in cancer. We therefore applied high-resolution chromosomal conformation capture sequencing to map the three-dimensional (3D) organization of the human locus encoding the key myeloid transcription factor PU.1 in healthy monocytes and acute myeloid leukemia (AML) cells. We identified a dynamic ∼75-kb unit (SubTAD) as the genomic region in which spatial interactions between PU.1 gene regulatory elements occur during myeloid differentiation and are interrupted in AML. Within this SubTAD, proper initiation of the spatial chromosomal interactions requires PU.1 autoregulation and recruitment of the chromatin-adaptor protein LDB1 (LIM domain-binding protein 1). However, once these spatial interactions have occurred, LDB1 stabilizes them independently of PU.1 autoregulation. Thus, our data support that PU.1 autoregulates its expression in a "hit-and-run" manner by initiating stable chromosomal loops that result in a transcriptionally active chromatin architecture.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30315124     DOI: 10.1182/blood-2018-02-834721

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  PU.1 chromosomal dynamics are linked to LDB1.

Authors:  Ann Dean
Journal:  Blood       Date:  2018-12-20       Impact factor: 22.113

2.  GATA2 and PU.1 Collaborate To Activate the Expression of the Mouse Ms4a2 Gene, Encoding FcεRIβ, through Distinct Mechanisms.

Authors:  Shin'ya Ohmori; Yasushi Ishijima; Suzuka Numata; Mai Takahashi; Masataka Sekita; Taichi Sato; Keisuke Chugun; Masayuki Yamamoto; Kinuko Ohneda
Journal:  Mol Cell Biol       Date:  2019-10-28       Impact factor: 4.272

3.  Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter.

Authors:  E van der Kouwe; G Heller; A Czibere; J A Pulikkan; C Agreiter; L H Castilla; R Delwel; A Di Ruscio; A K Ebralidze; M Forte; F Grebien; E Heyes; L Kazianka; J Klinger; C Kornauth; T Le; K Lind; I A M Barbosa; T Pemovska; A Pichler; A-S Schmolke; C M Schweicker; H Sill; W R Sperr; A Spittler; S Surapally; B Q Trinh; P Valent; K Vanura; R S Welner; J Zuber; D G Tenen; P B Staber
Journal:  Blood       Date:  2021-10-14       Impact factor: 25.476

4.  Blood stem cell PU.1 upregulation is a consequence of differentiation without fast autoregulation.

Authors:  Nouraiz Ahmed; Martin Etzrodt; Philip Dettinger; Tobias Kull; Dirk Loeffler; Philipp S Hoppe; James S Chavez; Yang Zhang; Germán Camargo Ortega; Oliver Hilsenbeck; Hideaki Nakajima; Eric M Pietras; Timm Schroeder
Journal:  J Exp Med       Date:  2021-11-24       Impact factor: 17.579

5.  The Il6 -39 kb enhancer containing clustered GATA2- and PU.1-binding sites is essential for Il6 expression in murine mast cells.

Authors:  Shin'ya Ohmori; Jun Takai; Satoshi Uemura; Akihito Otsuki; Tetsuya Mori; Kinuko Ohneda; Takashi Moriguchi
Journal:  iScience       Date:  2022-08-14

Review 6.  Determinants and role of chromatin organization in acute leukemia.

Authors:  Celestia Fang; Sridhar Rao; John D Crispino; Panagiotis Ntziachristos
Journal:  Leukemia       Date:  2020-07-20       Impact factor: 11.528

7.  Stage-specific action of Runx1 and GATA3 controls silencing of PU.1 expression in mouse pro-T cells.

Authors:  Hiroyuki Hosokawa; Maria Koizumi; Kaori Masuhara; Maile Romero-Wolf; Tomoaki Tanaka; Toshinori Nakayama; Ellen V Rothenberg
Journal:  J Exp Med       Date:  2021-06-28       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.